Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01118975 · ClinicalTrials.gov registry record · Phase 1
GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01118975: Clinical Trial Phase 1 study, sponsored by University of Maryland, Baltimore.
NCT01118975 is a Phase 1 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01118975, a Phase 1 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This research is being done to find out how safe and how well the combination of lapatinib and vorinostat works against advanced cancers.
Primary Outcome
Safety and tolerability were assessed. Adverse events and dose limiting toxicities were recorded during an escalting dose pilot phase.
Interventions
- DRUG Vorinostat
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Why NCT01118975 stopped before completion
NCT01118975 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Vorinostat is the first listed.
NCT01118975 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01118975 about?
NCT01118975 is a clinical study titled "GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers". This research is being done to find out how safe and how well the combination of lapatinib and vorinostat works against advanced cancers.
What is the current status of trial NCT01118975?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-03. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01118975?
The interventions under investigation include: Vorinostat (DRUG), Lapatinib (DRUG).
Who is sponsoring clinical trial NCT01118975?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01118975's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia